NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT ...
What is Abrysvo used for? Abrysvo (respiratory syncytial virus vaccine) is commonly given to help prevent lower respiratory tract disease (such as pneumonia or bronchiolitis) caused by respiratory ...
A single 120µg dose of Abrysvo generated a strong neutralizing response against both RSV-A and RSV-B in immunocompromised adults. Positive topline data were announced from a phase 3 study evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results